Skip to content

Author

Hossam M. Ali

We have 3 of 27 papers

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Oct 2026

GLP-1 Receptor Agonists and Risk of Kidney Replacement Therapy and Health Care Utilization in Bipolar Disorder With Chronic Kidney Disease.

Objective: To examine whether glucagon-like peptide-1 receptor agonist (GLP-1 RA) use is associated with reduced risk of kidney replacement therapy (KRT) and health care utilization (HCU) compared with active comparators in adults with bipolar disorder (BD) and chronic kidney disease (CKD; stage ≤3). Methods: Using Tri...

Balwinder Singh, M. G. Gonzalez Suarez, Hossam M. Ali et al. · 0 citations
Open access Aug 2026

SGLT2 inhibitors versus GLP-1 receptor agonists and risk of kidney replacement therapy and healthcare utilization in bipolar disorder with chronic kidney disease: An active-comparator, new-user cohort study

Individuals with bipolar disorder (BD) face elevated rates of chronic kidney disease (CKD) and premature mortality yet remain underrepresented in cardiorenal trials. Although sodium-glucose cotransporter-2 inhibitors (SGLT2is) and glucagon-like peptide-1 receptor agonists (GLP-1 RAs) have established renoprotective ben...

Balwinder Singh, Feyza Yaylaci, Hossam M. Ali et al. · 0 citations
Review Open access Sep 2026

Modulation of GABA and Glutamate by Ketamine in Depression: A Systematic Review and Meta-Analysis of Magnetic Resonance Spectroscopy Studies

Rigorous RCTs with standardized protocols, larger sample sizes, uniform dosing, and systematic biomarker investigations are needed to clarify ketamine’s neurochemical mechanism and optimize ketamine’s clinical application in treatment-resistant depression.

Balwinder Singh, Hossam M. Ali, Alessandro Miola et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.